Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma

Belantamab mafodotin (Blenrep, GlaxoSmithKline) is indicated 'in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who have had at least one prior therapy including lenalidomide'.

The dosage schedule is available in the summary of product characteristics for belantamab mafodotin.

The list price for belantamab mafodotin is £16,848 per 100‑mg vial and £11,784 per 70‑mg vial (excluding VAT, company correspondence). The list price for pomalidomide ranges from £7,995.60 to £8,884 per 21‑pack of 1‑mg, 2‑mg, 3‑mg or 4‑mg tablets (excluding VAT; BNF online accessed December 2025).

GlaxoSmithKline has a commercial arrangement for belantamab mafodotin. This makes it available to the NHS with a discount. The size of the discount is commercial in confidence.

There are nationally available price reductions for pomalidomide with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence.

For information, GlaxoSmithKline did not disclose its Carbon Reduction Plan for UK carbon emissions.